Chris Garabedian, Xontogeny CEO
December 13, 2022 09:46 AM EST
Financing
R&D

Chris Garabe­di­an's Xon­toge­ny shep­herds two more com­pa­nies through $60M Se­ries A rounds

Katherine Lewin

News Reporter

Xon­toge­ny CEO Chris Garabe­di­an un­veiled two rounds of Se­ries A fi­nanc­ing on Tues­day: one for Tel­lus Ther­a­peu­tics, a neona­tal care com­pa­ny, and an­oth­er for Per­ox­itech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

FDA says Ozem­pic, We­govy short­age is over

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times